Skip to main content
Erschienen in: European Radiology 7/2019

11.03.2019 | Nuclear Medicine

Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy?

verfasst von: Hongjun Song, Yining Jiao, Weijun Wei, Xuhua Ren, Chentian Shen, Zhongling Qiu, Qingcheng Yang, Qian Wang, Quan-Yong Luo

Erschienen in: European Radiology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate whether tumor texture features derived from pretreatment with 18F-fluorodeoxyglucose positron emission tomography (FDG PET) can predict histological response or event-free survival (EFS) in patients with localized osteosarcoma of the extremities treated by neoadjuvant chemotherapy (NAC).

Methods

We retrospectively reviewed 35 patients with American Joint Committee on Cancer stage II extremity osteosarcoma treated with NAC and surgery. Primary tumor traditional parameters and texture features were measured for all 18F-FDG PET images prior to treatment. After surgery, histological responses to NAC were evaluated on the postsurgical specimens. A receiver operating characteristic curve (ROC) was constructed to evaluate the optimal predictive performance among the various indices. EFS was calculated using the Kaplan-Meier method and prognostic significance was assessed by Cox proportional hazards analysis.

Results

Pathologic examination revealed 16 (45.71%) good responders and 19 (54.29%) poor responders. Although both the texture features (least axis, dependence nonuniformity, run length nonuniformity, and size zone nonuniformity) and metabolic tumor volume (MTV) can predict tumor response of osteosarcoma to NAC, the traditional indicator MTV has the best performance according to ROC curve analysis (area under the curve = 0.918, p < 0.0001). In multivariate analysis, MTV (p < 0.0001), histological response (p = 0.0003), and texture feature of coarsenessNGTDM (neighboring gray tone difference matrix) (p = 0.005) were independently associated with EFS.

Conclusions

Intratumoral heterogeneity of baseline 18F-FDG uptake measured by PET texture analysis can predict tumor response and EFS of patients with extremity osteosarcoma treated by NAC, but the conventional parameter MTV provides better predictive power and is a strong independent prognostic factor.

Key Points

• The baseline 18 F-FDG PET tumor texture features can predict tumor NAC response for patients with osteosarcoma.
• Coarseness NGTDM is a new and independent prognostic factor for osteosarcoma.
• MTV provides the best predictive power and is a strong independent prognostic factor for patients with osteosarcoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat ESMO/European Sarcoma Network Working Group (2014) Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii113–iii123CrossRef ESMO/European Sarcoma Network Working Group (2014) Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii113–iii123CrossRef
2.
Zurück zum Zitat Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531–1543CrossRefPubMed Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531–1543CrossRefPubMed
3.
Zurück zum Zitat Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P (2005) Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 42:2836–2845 Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P (2005) Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer 42:2836–2845
4.
Zurück zum Zitat Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12:423–431CrossRefPubMed Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12:423–431CrossRefPubMed
5.
Zurück zum Zitat Bajpai J, Gamnagatti S, Kumar R et al (2011) Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol 41:441–450CrossRefPubMed Bajpai J, Gamnagatti S, Kumar R et al (2011) Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis. Pediatr Radiol 41:441–450CrossRefPubMed
6.
Zurück zum Zitat Byun BH, Kong CB, Park J et al (2013) Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities. J Nucl Med 54:1725–1732CrossRefPubMed Byun BH, Kong CB, Park J et al (2013) Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities. J Nucl Med 54:1725–1732CrossRefPubMed
7.
Zurück zum Zitat Byun BH, Kong CB, Lim I et al (2013) Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med 54:1053–1059CrossRefPubMed Byun BH, Kong CB, Lim I et al (2013) Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med 54:1053–1059CrossRefPubMed
8.
Zurück zum Zitat Byun BH, Kong CB, Lim I et al (2014) Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18F-FDG PET/CT and MRI. Eur J Nucl Med Mol Imaging 41:1553–1562CrossRefPubMed Byun BH, Kong CB, Lim I et al (2014) Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18F-FDG PET/CT and MRI. Eur J Nucl Med Mol Imaging 41:1553–1562CrossRefPubMed
9.
Zurück zum Zitat Palmerini E, Colangeli M, Nanni C et al (2017) The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging 44:215–223CrossRefPubMed Palmerini E, Colangeli M, Nanni C et al (2017) The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging 44:215–223CrossRefPubMed
10.
Zurück zum Zitat Davis JC, Daw NC, Navid F et al (2018) 18F-FDG uptake during early adjuvant chemotherapy predicts histologic response in pediatric and young adult patients with osteosarcoma. J Nucl Med 59:25–30CrossRefPubMedPubMedCentral Davis JC, Daw NC, Navid F et al (2018) 18F-FDG uptake during early adjuvant chemotherapy predicts histologic response in pediatric and young adult patients with osteosarcoma. J Nucl Med 59:25–30CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Rajendran JG, Schwartz DL, O’Sullivan J et al (2006) Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12:5435–5441CrossRefPubMedPubMedCentral Rajendran JG, Schwartz DL, O’Sullivan J et al (2006) Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12:5435–5441CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat van Velden FH, Cheebsumon P, Yaqub M et al (2011) Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging 38:1636–1647CrossRefPubMedPubMedCentral van Velden FH, Cheebsumon P, Yaqub M et al (2011) Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging 38:1636–1647CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Asselin MC, O’Connor JP, Boellaard R et al (2012) Quantifying heterogeneity in human tumours using MRI and PET. 48:447–455 Asselin MC, O’Connor JP, Boellaard R et al (2012) Quantifying heterogeneity in human tumours using MRI and PET. 48:447–455
14.
Zurück zum Zitat Cook GJ, O’Brien ME, Siddique M et al (2015) Non-small cell lung cancer treated with erlotinib: heterogeneity of (18)F-FDG uptake at PET-association with treatment response and prognosis. Radiology 276:883–893CrossRefPubMed Cook GJ, O’Brien ME, Siddique M et al (2015) Non-small cell lung cancer treated with erlotinib: heterogeneity of (18)F-FDG uptake at PET-association with treatment response and prognosis. Radiology 276:883–893CrossRefPubMed
15.
Zurück zum Zitat Lovinfosse P, Polus M, Van Daele D et al (2018) FDG PET/CT radiomics for predicting the outcome of locally advanced rectalcancer. Eur J Nucl Med Mol Imaging 45:365–375CrossRefPubMed Lovinfosse P, Polus M, Van Daele D et al (2018) FDG PET/CT radiomics for predicting the outcome of locally advanced rectalcancer. Eur J Nucl Med Mol Imaging 45:365–375CrossRefPubMed
16.
Zurück zum Zitat Beukinga RJ, Hulshoff JB, van Dijk LV et al (2017) Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer with textural features derived from pretreatment (18) F-FDG PET/CT imaging. J Nucl Med 58:723–729CrossRefPubMed Beukinga RJ, Hulshoff JB, van Dijk LV et al (2017) Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer with textural features derived from pretreatment (18) F-FDG PET/CT imaging. J Nucl Med 58:723–729CrossRefPubMed
17.
Zurück zum Zitat Cheng NM, Fang YH, Lee LY et al (2015) Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Eur J Nucl Med Mol Imaging 42:419–428CrossRefPubMed Cheng NM, Fang YH, Lee LY et al (2015) Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Eur J Nucl Med Mol Imaging 42:419–428CrossRefPubMed
18.
Zurück zum Zitat Rosen G, Marcove RC, Huvos AG et al (1983) Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 106(Suppl):55–67CrossRefPubMed Rosen G, Marcove RC, Huvos AG et al (1983) Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 106(Suppl):55–67CrossRefPubMed
19.
Zurück zum Zitat Yushkevich PA, Piven J, Hazlett HC et al (2006) User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 31:1116–1128 Yushkevich PA, Piven J, Hazlett HC et al (2006) User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 31:1116–1128
20.
Zurück zum Zitat van Griethuysen JJM, Fedorov A, Parmar C et al (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77:e104–e107CrossRefPubMedPubMedCentral van Griethuysen JJM, Fedorov A, Parmar C et al (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77:e104–e107CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ (2013) Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging 40:133–140 Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ (2013) Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging 40:133–140
22.
Zurück zum Zitat Im HJ, Kim TS, Park SY et al (2012) Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging 39:39–49CrossRefPubMed Im HJ, Kim TS, Park SY et al (2012) Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging 39:39–49CrossRefPubMed
23.
Zurück zum Zitat Coffin CM, Lowichik A, Zhou H (2005) Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist. Am J Clin Pathol 123:75–90 ReviewCrossRefPubMed Coffin CM, Lowichik A, Zhou H (2005) Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist. Am J Clin Pathol 123:75–90 ReviewCrossRefPubMed
24.
Zurück zum Zitat Greene FL (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New York, pp 187–192CrossRef Greene FL (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New York, pp 187–192CrossRef
26.
Zurück zum Zitat Chen HH, Chiu NT, Su WC, Guo HR, Lee BF (2012) Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 264:559–566 Chen HH, Chiu NT, Su WC, Guo HR, Lee BF (2012) Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 264:559–566
27.
Zurück zum Zitat Kong CB, Byun BH, Lim I et al (2013) 18F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging 40:728–736CrossRefPubMed Kong CB, Byun BH, Lim I et al (2013) 18F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging 40:728–736CrossRefPubMed
28.
Zurück zum Zitat Im HJ, Zhang Y, Wu H et al (2018) Prognostic value of metabolic and volumetric parameters of FDG PET in pediatric osteosarcoma: a hypothesis-generating study. Radiology 287:303–312CrossRefPubMed Im HJ, Zhang Y, Wu H et al (2018) Prognostic value of metabolic and volumetric parameters of FDG PET in pediatric osteosarcoma: a hypothesis-generating study. Radiology 287:303–312CrossRefPubMed
29.
Zurück zum Zitat Bailly C, Leforestier R, Campion L et al (2017) Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. PLoS One 12:e0183841CrossRefPubMedPubMedCentral Bailly C, Leforestier R, Campion L et al (2017) Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. PLoS One 12:e0183841CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Tixier F, Le Rest CC, Hatt M et al (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52:369–378CrossRefPubMed Tixier F, Le Rest CC, Hatt M et al (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52:369–378CrossRefPubMed
31.
Zurück zum Zitat Yu H, Caldwell C, Mah K et al (2009) Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imaging 28:374–383CrossRefPubMed Yu H, Caldwell C, Mah K et al (2009) Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imaging 28:374–383CrossRefPubMed
32.
Zurück zum Zitat Cook GJ, Yip C, Siddique M et al (2013) Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med 54:19–26CrossRefPubMed Cook GJ, Yip C, Siddique M et al (2013) Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med 54:19–26CrossRefPubMed
Metadaten
Titel
Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy?
verfasst von
Hongjun Song
Yining Jiao
Weijun Wei
Xuhua Ren
Chentian Shen
Zhongling Qiu
Qingcheng Yang
Qian Wang
Quan-Yong Luo
Publikationsdatum
11.03.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 7/2019
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-019-06074-2

Weitere Artikel der Ausgabe 7/2019

European Radiology 7/2019 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.